Zoster sine herpete following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient. (2022)

• Record Type: Journal Article
• Authors: Tanizaki, Ryutaro; Miyamatsu, Yayoi
• Is Part Of: IDCases. Volume 29(2022)
• Publication Date: 2022
• Subjects: Zoster sine herpete -- COVID-19 -- Varicella zoster virus -- mRNA vaccination; Communicable diseases -- Periodicals; Communicable Diseases -- Case Reports; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; 616.9
• DOI: 10.1016/j.idcr.2022.e01563
• Languages: English
• ISSNs: 2214-2509

Abstract

Abstract: As a result of the COVID-19 pandemic, mRNA vaccination has become widespread. Recently, it has been suggested that instances of herpes zoster increase following mRNA COVID-19 vaccination. Herein, we describe the first case of zoster sine herpete (ZSH) after mRNA vaccination for COVID-19. A 60-year-old Japanese immunocompetent man presented with fever, fatigue, headache, cervical pain, and lumbar pain, which developed after receiving a second dose of BNT162b2 mRNA COVID-19 vaccination. Whereas most symptoms improved with symptomatic treatment, headache and numbness of the right forehead persisted in areas innervated by the trigeminal and second and third cervical nerves. Based on positive results of an enzyme-linked immunosorbent assay examination for anti-VZV IgM, ZSH was diagnosed, and amitriptyline improved the patient's symptoms. Diagnosis of ZSH is challenging due to the lack of a characteristic herpes zoster rash. Physicians should be aware that ZSH can develop after mRNA vaccination.